An observational study in Elderly Patients, Coronary Heart Disease and Drug Therapy, sponsored by Beijing Anzhen Hospital. Not yet recruiting. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2022-02-18.
Sponsored by Beijing Anzhen Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Coronary Disease by Beijing Anzhen Hospital — 4 open to participants now, 6 under way, none of them phase 3. Coronary Disease · Beijing Anzhen Hospital.
Among the 13 studies in Coronary Disease by Beijing Anzhen Hospital, this one is one of 2 that started in 2022, is one of 4 observational ones, and was the 7th registered.
1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →4 of the 13 studies in Coronary Disease by Beijing Anzhen Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Anzhen Hospital · Sites in China
Ages 18+
Beijing Anzhen Hospital · Sites in China
Ages 60+ · Healthy volunteers
Beijing Anzhen Hospital
Ages 18+
By country, each count listing its studies:
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15,000 is above the median of 916 across 478 observational studies indexed under Coronary Disease.
Median enrollment 224 across the 9 interventional studies, 22,500 across the 4 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Beijing Anzhen Hospital is the lead sponsor of 194 studies on the registry; 103 are open to participants now.
1 of the studies in Coronary Disease by Beijing Anzhen Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07332494Beijing Anzhen HospitalDigital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD) | 2027-10-10 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Coronary Disease by Beijing Anzhen Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A registry study on drug therapy and clinical outcomes in elderly patients with coronary heart disease
Elderly patients (≥65 years) with coronary heart disease who discharged at Beijing Anzhen Hospital from January 1, 2019.Those who fill the inclusion criteria at screening will be invited for the registry study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
main adverse cardiovascular and cerebrovascular events (MACCE)
MACCE will be defined as all-cause death, non-fatal stroke, non-fatal myocardial infarction (MI), and ischemic-driven revascularization
Time frame: up to 3 years
Adverse drug reaction
Adverse drug reaction will be defined as any adverse reactions in the patients
Time frame: up to 3 years
No study locations are listed for this record.
Start is estimated for Feb 2022; primary completion for Dec 2024, 34 months later.
Of 132 non-industry observational studies under Coronary Disease, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 192. This study's planned 34 months is below that.
Counting every sponsor, half of 154 studies reached it within 47 months; a quarter within 21 and three quarters within 123.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.